CTOs on the Move

Eichen Crutchlow Zaslow LLP

www.njadvocates.com

 
Eichen Crutchlow Zaslow LLP, with offices located in Edison, New Jersey, is recognized as one of the pre-eminent medical malpractice and personal injury law firms in New Jersey. The firm is highly regarded among legal professionals for their effective and aggressive representation based on intelligent and innovative strategies for recovering maximum compensation on behalf of victims of negligence. Clients recognize the attorneys and staff for providing the highest level of responsive client service and compassionate understanding of how devastating a catastrophic personal injury or death can be to an individual and family. The attorneys have extensive experience in all areas of ...
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Similar Companies

Linger Photo Engraving

Linger Photo Engraving is a Cincinnati, OH-based company in the Business Services sector.

Information Services Group

Information Services Group, Inc. (ISG) was founded in 2006 to build an industry-leading, high-growth, information-based services company by acquiring and growing businesses in advisory, data, business and media information services.

Doosan Infracore International Corporate Cente

Doosan Infracore International Corporate Cente is a Charlotte, NC-based company in the Business Services sector.

Caribou Communications

Caribou Communications is a San Francisco, CA-based company in the Business Services sector.

Skye Bioscience Inc.

Skye Bioscience Inc. is a clinical-stage biotechnology company based in San Diego, California. The company focuses on developing innovative therapeutics for metabolic diseases, particularly obesity, by modulating the endocannabinoid system. Skye Bioscience is advancing its lead product, Nimacimab, a monoclonal antibody that targets peripheral CB1 receptors. This treatment aims to provide effective weight loss solutions while minimizing neuropsychiatric side effects associated with previous therapies. Nimacimab is currently in a Phase 2 trial, evaluating its efficacy in weight loss and metabolic health. The company is also exploring combination therapies to enhance treatment outcomes. Skye Bioscience positions Nimacimab as a potential alternative to existing GLP-1-based therapies, targeting patients who need sustainable weight loss with improved safety profiles. The obesity drug market presents significant opportunities, and Skye is actively participating in clinical trials and industry conferences to advance its mission in metabolic health.